Clinical Features of Type B Insulin Resistance in Japanese Patients: Case Report and Survey-Based Case Series Study
Table 5
Treatment and comorbidity.
Group
A
B
C
Blood glucose pattern
Hyperglycemia
Hypoglycemia
Hyperglycemia and hypoglycemia
Total
value (Fisher’s exact test)
7
10
4
21
PSL administration (%)
85.7
100.0
75.0
88.9
Immunosuppressant administration other than PSL (%)
42.9
57.1
100.0
61.1
IGF-1 administration (%)
71.4
14.3
0
37.5
SLE (%)
42.9
40.0
25.0
38.1
Autoimmune diseases other than SLE (%)
57.1
66.6
75.0
65.0
Helicobacter pylori positive (%)
66.7
37.5
33.3
42.9
Diagnosis of T2DM before the onset of TBIR (%)
28.6
44.4
66.7
42.1
ANA positive (%)
100.0
60.0
50.0
71.4
Each item other than the number of patients is shown in the corresponding ratio. ANA: antinuclear antibody; BG: blood glucose; IGF-1: insulin-like growth factor-1; PSL: prednisolone; SLE: systemic lupus erythematosus; T2DM: type 2 diabetes mellitus; TBIR: type B insulin resistance. For all items, the answers obtained for each item were tabulated.
